Omnicell Inc
$ 40.48
5.25%
03 Dec - close price
- Market Cap 1,859,418,000 USD
- Current Price $ 40.48
- High / Low $ 40.59 / 38.31
- Stock P/E 94.14
- Book Value 27.21
- EPS 0.43
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.02 %
- 52 Week High 47.82
- 52 Week Low 22.66
About
Omnicell, Inc. is a leading provider of sophisticated medication management and adherence solutions, dedicated to enhancing patient safety and operational efficiency within healthcare systems and pharmacies worldwide. Based in Mountain View, California, the company offers an innovative technology platform featuring cutting-edge medication dispensing systems, robotic pharmacy solutions, and comprehensive analytics designed to optimize workflows and enhance clinical outcomes. With a strategic focus on reducing healthcare costs and improving automation, Omnicell is well-equipped to address the increasing demand for streamlined operations in a dynamic healthcare landscape.
Analyst Target Price
$47.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-31 | 2025-05-06 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-08-01 | 2023-05-02 | 2023-02-28 |
| Reported EPS | 0.51 | 0.45 | 0.26 | 0.6 | 0.56 | 0.51 | 0.03 | 0.33 | 0.62 | 0.57 | 0.39 | 0.33 |
| Estimated EPS | 0.36 | 0.27 | 0.2 | 0.58 | 0.42 | 0.14 | -0.09 | 0.15 | 0.47 | 0.28 | 0.07 | 0.09 |
| Surprise | 0.15 | 0.18 | 0.06 | 0.02 | 0.14 | 0.37 | 0.12 | 0.18 | 0.15 | 0.29 | 0.32 | 0.24 |
| Surprise Percentage | 41.6667% | 66.6667% | 30% | 3.4483% | 33.3333% | 264.2857% | 133.3333% | 120% | 31.9149% | 103.5714% | 457.1429% | 266.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMCL
2025-10-19 21:33:09
Omnicell, Inc. adopted new bylaws, effective immediately, to enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, address Rule 14a-19, and clarify personal jurisdiction. These changes, effective September 30, 2025, impact the company’s governance and stakeholder engagement. Analysts currently rate OMCL as a Hold with a $34.00 price target, and TipRanks' AI Analyst Spark rates it Neutral due to stable financials but cautions on high valuation and technical indicators.
2025-10-17 15:40:03
This article evaluates Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS) as potential value stocks within the Medical Info Systems sector. It suggests that OMCL appears to be the superior option for value investors due to its stronger Zacks Rank, better earnings outlook improvements, and more attractive valuation metrics compared to HIMS.
2025-10-17 00:40:30
Dimensional Fund Advisors LP increased its stake in Omnicell Inc. by adding 197,462 shares at $30.45 each, bringing its total holdings to 2,364,068 shares. This strategic move by the firm, known for its academic research-guided investment strategies, reflects confidence in Omnicell despite its current undervaluation and challenges in growth and momentum. Omnicell Inc, a healthcare automation provider, is considered significantly undervalued with a GF Value of $43.61, and other gurus also hold positions in the company.
2025-10-16 06:53:52
Argus has lowered its target price for Omnicell Inc. (OMCL) to $31.00, while the current price stands at $30.07. The company, which provides automation and business analytics software for healthcare providers, has a sector rating of Healthcare. The article hints at premium research reports offering more detailed insights.
2025-10-12 07:31:47
Mirae Asset Global Investments Co. Ltd. has increased its stake in Omnicell, Inc. (OMCL). This comes as several other institutional investors also adjusted their positions in the company, which saw its stock trade down by 4.5% to $33.16. Analysts have issued "overweight" ratings for Omnicell, projecting price objectives between $40.00 and $55.00.
2022-11-30 13:11:00
Health-tech company Omnicell Inc. announced plans to reduce its workforce by approximately 9%, affecting 350 employees, as part of expense containment efforts due to macroeconomic headwinds. The company expects to incur about $17.0 million in non-recurring restructuring and related charges, primarily for severance and benefits, with the majority in Q4 2022. The plan is expected to be substantially completed by the end of Q1 2023.
